PUBLISHER: DelveInsight | PRODUCT CODE: 1226613
PUBLISHER: DelveInsight | PRODUCT CODE: 1226613
"JYSELECA Market Drug Insight and Market Forecast - 2032" report provides comprehensive insights about JYSELECA for Ulcerative Colitis (UC) in the seven major markets. A detailed picture of the JYSELECA for ulcerative colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the JYSELECA for ulcerative colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JYSELECA market forecast analysis for ulcerative colitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ulcerative colitis.
JYSELECA (Filgotinib) is an orally bioavailable, investigational agent with potential anti-inflammatory and immunomodulating activities discovered and developed by Galapagos collaborating with Gilead. It is a selective JAK1 (Janus kinase 1) inhibitor. JAK1 is an enzyme with an essential role in promoting biologic responses induced by a subset of cytokine receptors, proteins that lead to inflammation. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling as JAK1 mediates signaling of many pro-inflammatory cytokines.
Dosage
The recommended dose for induction and maintenance treatment is 200 mg once daily. For patients with UC who do not show an adequate therapeutic benefit during the initial 10 weeks of treatment, 12 additional weeks of induction treatment with filgotinib 200 mg once daily may relieve symptoms. Patients who have not shown any therapeutic benefit after 22 weeks of treatment should discontinue filgotinib.
Mechanism of action
Filgotinib is adenosine triphosphate (ATP)-a competitive and reversible inhibitor of the JAK family. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane. JAK1 is important in mediating inflammatory cytokine signals, JAK2 in mediating myelopoiesis and erythropoiesis, and JAK3 plays critical roles in immune homeostasis and lymphopoiesis. JAKs phosphorylate and activate signal transducers and activators of transcription (STATs) within the signaling pathway, which modulate intracellular activity, including gene expression. Filgotinib modulates these signaling pathways by preventing the phosphorylation and activation of STATs. In biochemical assays, filgotinib preferentially inhibited the activity of JAK1 and showed >fivefold higher potency of filgotinib for JAK1 over JAK2, JAK3, and TYK2. In human cellular assays, filgotinib preferentially inhibited JAK1/JAK3-mediated signaling downstream of the heterodimeric cytokine receptors for interleukin (IL)-2, IL-4, and IL-15, JAK1/2-mediated IL-6, and JAK1/TYK2-mediated type I interferons, with functional selectivity over cytokine receptors that signal via pairs of JAK2 or JAK2/TYK2. GS-829845, the primary metabolite of filgotinib, was approximately 10-fold less active than filgotinib in in vitro assays while exhibiting a similar JAK1 preferential inhibitory activity. In an in vivo rat model, the overall pharmacodynamics effect was predominantly driven by the metabolite.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
JYSELECA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of JYSELECA for ulcerative colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of JYSELECA for ulcerative colitis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions